Body composition and its association with fatigue in the first 2 years after colorectal cancer diagnosis

H. van Baar 1 · M. J. L. Bours 2 · S. Beijer 3 · M. van Zutphen 1 · F. J. B. van Duijhoven 1 · D. E. Kok 1 · E. Wesselink 1 · J. H. W. de Wilt 4 · E. Kampman 1 · R. M. Winkels 1

Received: 18 May 2020 / Accepted: 6 October 2020 / Published online: 17 October 2020 © The Author(s) 2020

Abstract

Purpose Persistent fatigue among colorectal cancer (CRC) patients might be associated with unfavorable body composition, but data are sparse and inconsistent. We studied how skeletal muscle index (SMI), skeletal muscle radiodensity (SMR), visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) at diagnosis are associated with fatigue up to 24 months post-diagnosis in stage I–III CRC patients.

Methods SMI, SMR, VAT, and SAT were assessed among 646 CRC patients using pre-treatment computed tomography images. Fatigue at diagnosis, at 6, and 24 months post-diagnosis was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. The association of SMI, SMR, VAT, and SAT with fatigue (yes/no) was assessed using confounder-adjusted restricted cubic spline analyses.

Results Prevalence of fatigue at diagnosis was 18%, at 6 months 25%, and at 24 months 12%. At diagnosis, a significant (p = 0.01) non-linear association of higher levels of SAT with higher prevalence of fatigue was observed. Lower levels of SMR were linearly associated with higher prevalence of fatigue at 6 months post-diagnosis (overall association p = 0.02). None of the body composition parameters were significantly associated with fatigue at 24 months.

Conclusion Having more SAT was associated with more fatigue at diagnosis, while low levels of SMR were associated with more fatigue at 6 months post-diagnosis.

Implications for Cancer Survivors Our results suggest that it may be interesting to investigate whether interventions that aim to increase SMR around the time of diagnosis may help to lower fatigue. However, more knowledge is needed to understand the mechanisms behind the association of SMR with fatigue.

Keywords Fatigue · Colorectal cancer · Adipose tissue · Muscle mass · Fat mass · Skeletal muscle radiodensity

Introduction

Fatigue is highly prevalent among stage I–III colorectal cancer (CRC) patients. Fatigue is often already experienced before diagnosis [1] and can persist for years after treatment. The highest prevalence (up to 85%) of fatigue is seen during and shortly after treatment [2, 3], and although the prevalence decreases in the years after treatment, up to 40% of CRC patients experience fatigue in the first 5 years after diagnosis [4]. Fatigue is one of the most debilitating side effects of cancer and has a substantial negative impact on mood, work, social relationships, and overall quality of life [2].

Fatigue among cancer survivors is thought to have a multifactorial etiology. Fatigue has been associated with treatment (radio- and chemotherapy), stage of disease, presence of (multiple) comorbidities, specific medications with sedating side effects, psychological factors (e.g., depression), decreased
physical activity, and malnutrition [2, 5–7]. Several studies investigated whether there was an association between obesity and fatigue among cancer patients. Although some studies observed that obesity was associated with more fatigue [8–10], other studies did not find a significant association [11–13]. The use of body mass index (BMI) as measure of obesity might explain the mixed results in these studies: BMI does not take adipose tissue distribution into account and is an unreliable proxy for adiposity [14]. In cancer populations, computed tomography (CT) imaging is a key part of diagnosis and planning of treatment. Through those images, opportunistic imaging of skeletal muscle and adipose tissue became popular over the last two decades. These existing CT images are used to quantify visceral and subcutaneous adipose tissue (VAT and SAT respectively), skeletal muscle mass, and skeletal muscle radiodensity (SMR, indirect measurement of fat infiltration within the muscle cell, where lower levels of radiodensity indicate higher fat infiltration). Associations between CT-determined body composition and fatigue in cancer survivors have been studied in only a few studies, with mixed results. Two studies conducted among 734 stage IIIb/IV non-small cell lung cancer patients [15] and 151 advanced colorectal, breast, or prostate cancer patients [16], respectively, both observed that less skeletal mass at diagnosis was associated with higher levels of pre-treatment fatigue among men. Both studies did not observe significant associations among women. Another study conducted among 96 stage I–III CRC survivors who were on average 5.2 years post-diagnosis did not find an association between skeletal muscle mass at diagnosis and levels of fatigue at that point post-diagnosis [17]. The latter study also investigated VAT and SMR and did not find an association between those body composition parameters and fatigue [17]. The association between SMR at diagnosis and pretreatment fatigue was also investigated among the earlier quoted study among non-small cell lung cancer patients, and no significant association was observed there either [15]. To our knowledge, no study has investigated the association between SAT and fatigue among cancer patients.

The aim of the current study was to investigate the association of body composition parameters (Skeletal Muscle Index (SMI), SMR, VAT, and SAT) at diagnosis with fatigue at three timepoints (diagnosis, 6 months, and 24 months post-diagnosis) in stage I–III CRC patients.

Methods

Study population

For this study, we used data of the ongoing COLON study: Colorectal cancer: Longitudinal, Observational study on Nutritional and lifestyle factors that may influence colorectal tumor recurrence, survival, and quality of life [18]. In eleven participating hospitals, hospital staff invited eligible patients to participate in the COLON study shortly after diagnosis and before scheduled surgery. Patients were not eligible if they had a history of CRC, a previous (partial) bowel resection, known hereditary CRC, inflammatory bowel disease, dementia, or another mental condition limiting their ability to fill out surveys, or were non-Dutch speaking. For the present study, participants diagnosed between 2010 and 2015, from seven of the eleven participating hospitals, were included. For the participants from the other hospitals and participants included after 2015, no CT images had been retrieved from the medical records at time of the current analyses. Exclusion criteria for the present analyses were missing data on fatigue, height, stage of disease, or comorbidities; stage IV CRC; and missing or unusable CT images (i.e., CT images of poor quality or scans where muscle tissue was partly cut off). In addition, we only used data of patients who had a pretreatment CT image performed no longer than 3 months before diagnosis, as we considered that to be representative for body composition at diagnosis.

The COLON study was approved by the Committee on Research involving Human Subjects, region Arnhem–Nijmegen, the Netherlands, and all study participants provided written informed consent.

Fatigue

Fatigue was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) version 3.0 [19] at three points in time: at diagnosis and 6 and 24 months after diagnosis. In the EORTC QLQ-C30, the fatigue subscale is comprised of three items (During the past week: Did you need to rest?, Have you felt weak?, Were you tired?) with four response options used to score the items: “Not at all,” “A little,” “Quite a bit,” and “Very much.” The raw score for fatigue was linearly transformed into a score of 0–100 points as described earlier [19], with a higher score indicating higher levels of fatigue. A score of $>39$ was defined as having clinically relevant fatigue as recommended elsewhere [20, 21].

Body composition

Cross-sectional areas ($\text{cm}^2$) of skeletal muscle, VAT, and SAT were assessed using standard radiodensity thresholds measured in Hounsfield units (HU) in preoperative CT images at the level of the 3rd lumbar vertebrae using Slice-O-Matic 5.0 (Tomovision, Montreal, Canada). For skeletal muscle, the threshold values were between $−29$ and $+150$ HU, for VAT between $−150$ and $−50$ HU, and for SAT between $−190$ and $−30$ HU [22, 23]. The skeletal muscle cross-sectional area was adjusted for height squared ($\text{cm}^2/\text{m}^2$) to calculate skeletal muscle index (SMI). SMR was assessed as the mean...
radiodensity of the total skeletal muscle cross-sectional area at the level of the 3rd lumbar vertebrae.

**Demographic, lifestyle, and clinical data**

Demographic information including age at diagnosis, sex, and weight and height was collected using self-administered questionnaires. Physical activity was assessed at diagnosis, 6, and 24 months post-diagnosis using the validated Short QUestionnaire to ASsess Health-enhancing physical activity (SQUASH) [24]. Data on stage of disease, tumor site, treatment, comorbidities, complications after surgery, and stoma placement after surgery were retrieved from the Dutch ColoRectal Audit [25].

**Power calculation and data analysis**

We calculated that 600 patients were needed to have 80% power to detect a prevalence ratio of larger than 1.6 or smaller than 0.6, assuming that 40% of the population would suffer from fatigue [4, 26] and an alpha of 0.05.

Demographic, clinical, and lifestyle characteristics are presented as mean and standard deviation (SD) for continuous variables with normal distribution, median, and interquartile range (IQR) for continuous variables without normal distribution or frequency and percentage for categorical variables. Differences in patient characteristics were analyzed using the independent T test (continuous variables) or Pearson $\chi^2$ test (categorical variables).

Restricted cubic spline (RCS) analyses [27] were used to investigate associations of SMI, SMR, VAT, and SAT with fatigue at all timepoints and to assess whether associations were non-linear. Knots were placed at the 5th, 50th, and 95th percentiles of SMI, SMR, VAT, or SAT. Prevalence ratios (PR) and 95% confidence intervals (CI) for the associations of SMI, SMR, VAT, and SAT with fatigue were estimated using RCS functions in Cox proportional hazard regression models with a fixed timepoint. PRs were chosen instead of odd ratios since the latter tend to overestimate the size of the association when the outcome is common [28]. Median value for each body composition parameter was set as the reference in each model. As a complement to the graphic presentation of the RCS graphs, PRs with 95% confidence intervals for specific SMI, SMR, VAT, and SAT values were calculated using the RCS analyses.

All analyses were tested for effect modification by gender, by calculating the $p$ value for interaction. In none of the analyses, gender was identified as effect modifier. Potential confounders were included in the final model if they change the PR for fatigue with 10% or more when the variable was individually added to a crude model including SMI/SMR/VAT/SAT, age, stage of disease, and gender. For all analyses, potential confounders were SMI (continuous, in the model for SMR, VAT, and SAT), SMR (continuous, in the model for SMI, VAT, and SAT), total adipose tissue (calculated as sum of VAT and SAT, continuous), comorbidities (0, 1, and $\geq$ 2), tumor site (colon/rectum), and physical activity (minutes per week of moderate-to-vigorous physical activity). For the analyses at 6 and 24 months, additional potential confounders were chemotherapy (yes/no), radiotherapy (yes/no), stoma placement after surgery (yes/no), and complications post-surgery (yes/no).

The statistical significance level for the analyses was set at $p < 0.05$. Statistical analyses were carried out using IBM SPSS v.23 (SPSS, Chicago, IL).

**Results**

**Study population**

The study population consisted of 960 patients, of which we had to exclude 192 patients because no suitable CT image was available; 68 patients because of stage IV disease; 11 patients because of missing information on stage of disease; and 63 patients because no fatigue data at diagnosis were available (Fig. 1). This resulted in a final dataset of 646 patients with fatigue data at diagnosis, 581 patients with also fatigue data at 6 months, and 496 patients with fatigue data at 24 months.

Baseline characteristics of the total study population and of patients with and without fatigue at the various timepoints are presented in Table 1. The average age of the total study population at diagnosis was 66.1 ± 8.8 years, 63% of the patients were men, and in 66% of the patients the tumor was located in the colon. The majority of the patients had stage III disease (46%), while the percentages of patients with stage I or II disease were 27% and 28%, respectively. At diagnosis, and at 6 and 24 months post-diagnosis, 18%, 25%, and 12% of the patients, respectively, experienced fatigue. Supplementary Tables 1 and 2 describe baseline characteristics by tertiles of SMI/SMR/VAT/SAT.

**Difference between patients with and without fatigue**

At diagnosis, age was similar for patients with and without fatigue, women more often reported fatigue, and patients with colon cancer more often experienced fatigue (Table 1). At this timepoint, patients with fatigue generally had more SAT.

Six months post-diagnosis, the patients who experienced fatigue were slightly younger, more often women, and received more often chemotherapy and/or radiotherapy. At 6 months post-diagnosis, the percentage of patients with colon cancer was almost similar between the group with and without fatigue. SMR was lower among patients with fatigue and patients with fatigue had more SAT.
At 24 months post-diagnosis, age was similar for patients with or without fatigue and the percentage of men was higher among patients with fatigue. The percentage of patients who received chemotherapy was almost similar between the group with and without fatigue, while slightly more patients with fatigue 24 months post-diagnosis received radiotherapy. At 24 months, SMR was lower among patients with fatigue and patients with fatigue had more VAT.

At all three timepoints, the number of hours of moderate-to-vigorous physical activity was lower among the patients with fatigue, and the percentage of patients with two or more comorbidities at diagnosis was higher among patients with fatigue.

**Association between body composition and fatigue**

No association was observed between SMI and fatigue at any of the three timepoints (test for overall association at diagnosis and at 6 and 24 months post-diagnosis: $p = 0.36$, $p = 0.80$, and $p = 0.54$, respectively) (Fig. 2a). PRs with 95% confidence intervals for specific SMI values can be found in Table 2. A significant linear association between SMR and fatigue was observed at 6 months post-diagnosis (test for overall association $p = 0.02$, test for non-linearity $p = 0.14$), where lower levels of SMR were associated with higher prevalence of fatigue (see Fig. 2b). Table 2 shows that relative to the median, SMR levels below the median were significantly associated with higher fatigue prevalence. No significant associations were observed between SMR and fatigue at diagnosis (test for overall association $p = 0.74$) and at 24 months post-diagnosis (test for overall association at diagnosis $p = 0.17$).

For VAT, no significant association with fatigue was observed at any of the timepoints (test for overall association at diagnosis and at 6 and 24 months post-diagnosis: $p = 0.63$, $p = 0.56$, and $p = 0.22$, respectively) (see Fig. 3a).

Levels of SAT were non-linearly associated with fatigue at diagnosis, where higher levels of SAT were significantly associated with higher prevalence of fatigue (test for overall association $p < 0.01$, test for non-linearity $p = 0.01$) (see Fig. 3b). Table 2 also illustrates that higher SAT levels relative to the median were associated with higher fatigue prevalence at baseline. At both 6 and 24 months, SAT was not associated with fatigue (test for overall association at 6 and 24 months post-diagnosis: $p = 0.63$ and $p = 0.22$, respectively).

**Discussion**

The present study is the first study to investigate associations of body composition at time of diagnosis with fatigue at diagnosis, and 6 and 24 months post-diagnosis in stage I–III CRC patients. Having more SAT at diagnosis was associated with higher prevalence of fatigue at diagnosis, while lower SMR levels at diagnosis were associated with fatigue at 6 months post-diagnosis.

We did not observe an association between low SMI and fatigue at diagnosis, while such an association of low SMI and more fatigue at cancer diagnosis was observed among men in two earlier studies among different cancer populations [15, 16]. Those two studies included mainly late-stage cancer patients, while the present study included stage I–III CRC patients. In late-stage cancer patients, low SMI might be more often the result of tumor-induced muscle degradation, while low SMI among stage I–III is most likely age and lifestyle related since cachexia is less common within patient group among these earlier stages [29]. Since fatigue is more prevalent among late-stage cancer patients [5], the association
Table 1  Characteristics of stage I–III colorectal cancer patients with or without fatigue at diagnosis, 6 months post-diagnosis, and 24 months post-diagnosis

| Fatigue | Total population at diagnosis n = 646 | Diagnosis | 6 months post-diagnosis | 24 months post-diagnosis |
|---------|--------------------------------------|-----------|-------------------------|--------------------------|
|         | Yes n = 114 (18%) No n = 532 (82%) | p value   | Yes n = 148 (25%) No n = 433 (75%) | p value |
| Age at diagnosis (years, mean (SD)) | 66.1 (8.8) | 66.0 (8.6) | 0.74 | 66.4 (10.3) | 66.6 (8.3) | < 0.01 | 66.0 (11.6) | 65.5 (8.4) | 0.72 |
| Men (n (%)) | 406 (63) | 61 (54) | 0.02 | 86 (58) | 283 (65) | 0.09 | 42 (69) | 270 (62) | 0.03 |
| Cancer stage (n %) | | | | | | | | |
| I | 174 (27) | 26 (23) | 17 (12) | 144 (33) | 15 (25) | 3 (54) | 13 (21) | 124 (29) | 0.18 |
| II | 178 (28) | 40 (35) | 22 (15) | 139 (32) | 13 (21) | 3 (54) | 17 (25) | 133 (31) | 0.03 |
| III | 294 (46) | 48 (42) | 109 (74) | 150 (35) | 15 (25) | 3 (54) | 17 (25) | 133 (31) | 0.03 |
| Tumor location (n %) | | | | | | | | |
| Colon | 426 (66) | 94 (83) | 92 (62) | 288 (67) | 37 (61) | 282 (65) | 0.27 |
| Rectal | 220 (34) | 20 (18) | 56 (38) | 145 (34) | 24 (39) | 153 (35) | 0.11 |
| Number of comorbidities at diagnosis (n %) | | | | | | | | |
| 0 | 230 (36) | 34 (30) | 50 (34) | 163 (38) | 17 (28) | 168 (39) | 0.11 |
| 1 | 167 (26) | 26 (23) | 30 (20) | 116 (27) | 9 (15) | 113 (26) | 0.21 |
| ≥2 | 246 (38) | 53 (47) | 67 (45) | 153 (35) | 34 (56) | 153 (35) | 0.19 |
| Radiotherapy (n %) | | | | | | | | |
| Yes | 171 (26) | 16 (14) | 50 (34) | 104 (24) | 21 (35) | 114 (26) | 0.21 |
| No | 490 (74) | 97 (86) | 97 (66) | 325 (75) | 39 (65) | 319 (74) | 0.21 |
| Chemotherapy (n %) | | | | | | | | |
| Yes | 191 (29) | 38 (33) | 74 (50) | 87 (20) | 18 (30) | 113 (26) | 0.21 |
| No | 471 (71) | 76 (67) | 73 (50) | 344 (79) | 43 (70) | 320 (74) | 0.52 |
| Physical activity (moderate-vigorous min/week, median (IQR)) | | | | | | | | |
| Diagnosis | 600 (285–1110) | 505 (229–983) | 630 (300–1140) | 0.21 | 265 (80–540) | 500 (240–870) | < 0.01 | 412 (118–840) | 570 (330–1020) | 0.05 |
| 6 months | | | | | | | | |
| 24 months | | | | | | | | |
| Skeletal muscle index (cm²/m², mean (SD)) | 47.7 (8.7) | 46.4 (7.8) | 48.1 (8.8) | 0.06 | 47.4 (8.9) | 48.0 (8.6) | 0.39 | 48.2 (7.6) | 47.9 (8.7) | 0.72 |
| Skeletal muscle radiodensity (HU, mean (SD)) | 37.0 (8.2) | 36.2 (8.4) | 37.3 (8.2) | 0.17 | 35.8 (9.3) | 37.7 (7.8) | 0.01 | 35.5 (8.2) | 37.8 (7.9) | 0.03 |
| Visceral adipose tissue (cm², median (IQR)) | 142 (73–217) | 131 (78–204) | 146 (74–219) | 0.61 | 140 (72–215) | 145 (76–215) | 0.66 | 174 (96–238) | 135 (65–208) | 0.05 |
| Subcutaneous adipose tissue (cm², median (IQR)) | 163 (118–214) | 162 (117–251) | 163 (119–212) | 0.61 | 183 (129–236) | 157 (116–203) | < 0.01 | 177 (129–235) | 163 (118–210) | 0.35 |

*At diagnosis data of 5 patients missing; †at diagnosis data of 4 patients missing; ‡at diagnosis data of 7 patients missing. SD, standard deviation; IQR, interquartile range; HU, Hounsfield unit.
Table 2  Estimated prevalence ratios for specific skeletal muscle index, skeletal muscle radiodensity, and visceral adipose tissue and subcutaneous adipose tissue values and fatigue, with median values as the reference category (i.e., for skeletal muscle index: 47.5 cm\(^2\)/m\(^2\); for skeletal muscle radiodensity: 37.2 HU; for visceral adipose tissue: 142.6 cm\(^2\); for subcutaneous adipose tissue: 162.9 cm\(^2\))

|                | Diagnosis | 6 months | 24 months |
|----------------|-----------|----------|-----------|
| **SMI (cm\(^2\)/m\(^2\))** |           |          |           |
| 30             | 0.65      | 0.27–1.56| 1.25      |
| 40             | 0.90      | 0.66–1.21| 1.07      |
| 50             | 0.98      | 0.91–1.06| 1.00      |
| 60             | 0.72      | 0.42–1.24| 1.06      |
| **SMR (HU)**   |           |          |           |
| 20             | 1.22      | 0.65–2.30| 2.04      |
| 30             | 1.08      | 0.88–1.32| 1.27      |
| 40             | 0.98      | 0.90–1.06| 0.96      |
| 50             | 0.92      | 0.53–1.60| 0.95      |
| **VAT (cm\(^2\))** |           |          |           |
| 50             | 0.90      | 0.61–1.32| 1.14      |
| 150            | 1.00      | 0.98–1.02| 1.00      |
| 250            | 0.92      | 0.71–1.19| 1.04      |
| 350            | 0.75      | 0.40–1.43| 1.20      |
| **SAT (cm\(^2\))** |           |          |           |
| 50             | 1.41      | 0.82–2.41| 0.87      |
| 150            | 1.02      | 0.97–1.06| 0.99      |
| 250            | 1.12      | 0.94–1.34| 1.10      |
| 350            | 1.70      | 1.20–2.42| 1.22      |

*Adjusted for age, gender, and stage of disease at all timepoints. **At diagnosis adjusted for age, gender, and stage of disease; at 6 and 24 months additionally adjusted for physical activity (minutes per week of moderate-to-vigorous physical activity). ***Adjusted for age, gender, and stage of disease and skeletal muscle radiodensity at all timepoints. PR, prevalence ratio; 95% CI, 95% confidence interval; SMI, skeletal muscle index; SMR, skeletal muscle radiodensity; SAT, visceral adipose tissue; VAT, subcutaneous adipose tissue.

between low SMI and fatigue among late-stage patients might be driven by the progressive tumor instead of low SMI itself. This might explain why no association was observed at diagnosis in the present study. In the present study, we also did not observe an association between SMI at diagnosis and fatigue 2 years after diagnosis. This is similar to what was observed in a study of van Roekel et al. [17]. In that study among stage I–III CRC patients, SMI was not associated with fatigue 2–10 years post-diagnosis.

In the present study, we observed that lower SMR levels were associated with higher prevalence of fatigue 6 months post-diagnosis, but not at diagnosis or 24 months post-diagnosis. Nevertheless, at 24 months, the shape of the RCS appeared similar to the shape of the association at 6 months, but did not reach statistical significance at 24 months. This may be the result of lower statistical power at the 24 month timepoint: at 24 months, the total number of participants in the dataset was lower than at the earlier timepoints, while the prevalence of fatigue at this timepoint was also lower than at the earlier timepoints. Upon diagnosis, fatigue may partly be cancer-related, but may also partly be pre-existing general fatigue, but we could not differentiate between the two in our study. At the 6 month timepoint, most patients will have completed the cancer treatment or will be about to complete chemotherapy. Therefore, at that point in time, fatigue is likely to be more cancer-related than upon diagnosis. As the underlying reasons for fatigue may differ between timepoints, the mechanisms and associations with body composition and SMR may also differ.

In our study, lower SMR was associated with more fatigue; prior research among cancer survivors have linked lower SMR to other outcomes, including worse physical function [30] and higher mortality [31–38]. This link may potentially partly be explained by increased pro-inflammatory cytokine production, as this has been reported with lower levels of SMR [39]. Those pro-inflammatory factors may increase the risk of fatigue. Another explanation might be that lower levels of SMR are usually seen in patients with an inferior overall condition (i.e., multiple comorbidities, higher ASA score) [40, 41]. Because of this, patients with low SMR may experience more (long-term) side effects from treatment. Further studies are needed to understand the mechanisms behind the association of low SMR with fatigue.

To the best of our knowledge, the present study was the first study to investigate the association of SAT with fatigue among cancer patients. The results from our study suggest that at time of diagnosis, high levels of SAT are associated with higher prevalence of fatigue. Upon diagnosis, fatigue may partly be cancer-related, but can also partly be pre-existing general fatigue. In the general population, more adiposity has been found to be associated with more physical fatigue, which has been attributed to higher adiposity giving rise to chronic low-grade inflammation. But, also, there data are not fully consistent [42]. Interestingly, the association was found only for SAT and not for VAT. This was somewhat unexpected, since VAT is known to be more metabolically active than SAT [43] and a higher inflammatory response seen with higher levels of VAT could have explained a potential association with fatigue. A potential reason for this is that the assessment of VAT from CT images may be less accurate than the assessment of SAT. Several authors have questioned the use of a single slice CT image to assess VAT because the natural movement of abdominal soft tissue might influence the amount of VAT shown at the level of L3 [44, 45]. This may result in higher variation and, therefore, less statistical power to detect associations.
A limitation of the study was that body composition data were only available at diagnosis; as in the Netherlands, CT images are only standard of care for diagnosis/staging, but not in the period of follow-up \[46\]. Therefore, we could not assess how SMI, SMR, VAT, and/or SAT change post-diagnosis and whether any changes impact the association with fatigue. A second limitation was that statistical power was lower at 24 months post-diagnosis than at the earlier timepoints. Strengths of this study were the use of CT images to assess body composition and the availability of fatigue data at multiple timepoints.
In conclusion, having more SAT was associated with more fatigue at diagnosis, while low levels of SMR were associated with more fatigue at 6 months post-diagnosis. Studies with longitudinal measurements of body composition and fatigue are needed to further increase our understanding on this topic and to investigate potential mechanisms. In addition, this suggests that it may be interesting to investigate whether interventions that aim to increase SMR around the time of diagnosis may help to lower fatigue.
Acknowledgments The authors would like to thank all participants, the involved co-workers in the participating hospitals, and the COLON investigators at Wageningen University & Research.

Funding The COLON study was financially supported by Wereld Kanker Onderzoek Fonds (WKOF) & World Cancer Research Fund International (WCRF International) as well as by funds from grant 2014/1179 as part of the World Cancer Research Fund International Regular Grant Programme, Alpe d’Huzes/Dutch Cancer Society (UM 2012-5653, UW 2013-5927, UW 2015-7946), and ERA-NET on Translational Cancer Research (TRANSCAN: Dutch Cancer Society (UW2013-6397, UW2014-6877), and the Netherlands Organization for Health Research and Development (ZonMW, the Netherlands).

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Ethical approval The study was performed in accordance with the Declaration of Helsinki. The COLON study (ClinicalTrials.gov Identifier: NCT03191110) was approved by the Committee on Research involving Human Subjects, region Arnhem–Nijmegen, the Netherlands.

Informed consent All participants of the COLON study provided written informed consent.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Hickok JT, Roscoe JA, Morrow GR, Mustian K, Okunieff P, Bole CW. Frequency, severity, clinical course, and correlates of fatigue in 372 patients during 5 weeks of radiotherapy for cancer. Cancer. 2005;104(8):1772–8.
2. Bower JE. Cancer-related fatigue—mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014;11(10):597–609.
3. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist. 2007;12(Supplement 1):4–10.
4. Thong MS, Mols F, Wang XS, Lemmens VE, Smilde TJ, van de Poll-Franse LV. Quantifying fatigue in (long-term) colorectal cancer survivors: a study from the population-based patient reported outcomes following initial treatment and long term evaluation of survivorship registry. Eur J Cancer. 2013;49(8):1957–66.
5. Mitchell SA. Cancer-related fatigue: state of the science. PM&R. 2010;2(5):364–83.
6. Aapro M, Scotté F, Bouillet T, Currow D, Viganò A. A practical approach to fatigue management in colorectal cancer. Clin Colorectal Cancer. 2017;16(4):275–85.
7. Vissers PAJ, Thong MSY, Pouwer F, Zanders MMJ, Coebergh JWW, van de Poll-Franse LV. The impact of comorbidity on Health-Related Quality of Life among cancer survivors: analyses of data from the PROFILES registry. J Cancer Surviv. 2013;7(4):602–13.
8. Schmidt ME, Chang-Claude J, Seibold P, Vrielinck A, Heinz J, Flesch-Janys D, et al. Determinants of long-term fatigue in breast cancer survivors: results of a prospective patient cohort study. Psycho-Oncology. 2015;24(1):40–6.
9. Courneya KS, Karvinen KH, Campbell KL, Pearcey RG, Dundas G, Capstick V, et al. Associations among exercise, body weight, and quality of life in a population-based sample of endometrial cancer survivors. Gynecol Oncol. 2005;97(2):422–30.
10. Oldenburg CS, Boll D, Nicolaie KA, Vos MC, Pijnenborg JM, Coebergh J-W, et al. The relationship of body mass index with quality of life among endometrial cancer survivors: a study from the population-based PROFILES registry. Gynecol Oncol. 2013;129(1):216–21.
11. van Veen MR, Mols F, Bours MJ, Weijenberg MP, Kampman E, Beijer S. Adherence to the World Cancer Research Fund/American Institute for Cancer Research recommendations for cancer prevention is associated with better health-related quality of life among long-term colorectal cancer survivors: results of the PROFILES registry. Support Care Cancer. 2019;27(12):4565–74.
12. Smits A, Lopes A, Das N, Bekkers R, Glaal K. The impact of BMI on quality of life in obese endometrial cancer survivors: does size matter? Gynecol Oncol. 2014;132(1):137–41.
13. Basen-Engquist K, Scruggs S, Jhingran A, Bodurka DC, Lu K, Ramondetta L, et al. Physical activity and obesity in endometrial cancer survivors: associations with pain, fatigue, and physical functioning. Am J Obstet Gynecol. 2009;200(3):288.e1–8.
14. Burkhauer RV, Cawley J. Beyond BMI: the value of more accurate measures of fatness and obesity in social science research. J Health Econ. 2008;27(2):519–29.
15. Bye A, Sjöblom B, Wentzel-Larsen T, Grønberg BH, Baracos VE, Hjermstad MJ, et al. Muscle mass and association to quality of life in non-small cell lung cancer patients. J Cachexia Sarcopenia Muscle. 2017;8(5):759–67.
16. Neeftjes ECW, Hurk RM, Blauwhoff-Buskermolen S, Vorst MJDL, Becker-Commissaris A, Schuuren MAE, et al. Muscle mass as a target to reduce fatigue in patients with advanced cancer. J Cachexia Sarcopenia Muscle. 2017;8(4):623–9.
17. van Roekel EH, Bours MJL, te Molder MEM, Breedveld-Peters JJL, Olde Damink SWM, Schouten MAJ, et al. Associations of adipose and muscle tissue parameters at colorectal cancer diagnosis with long-term health-related quality of life. Qual Life Res. 2017;26(7):1745–59.
18. Winkel’s R, Heine-Broiring R, Van Zutphen M, van Harten-Gerritsen S, Kok D, Van Duijnhooven F, et al. The COLON study: Colorectal cancer: Longitudinal, Observational study on Nutritional and lifestyle factors that may influence colorectal tumour recurrence, survival and quality of life. BMC Cancer. 2014;14(1):374.
19. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–76.
20. Giesinger JM, Kuijpers W, Young T, Tomaszewski KA, Friend E, Zabernigg A, et al. Thresholds for clinical importance for four key domains of the EORTC QLQ-C30: physical functioning, emotional functioning, fatigue and pain. Health Qual Life Outcomes. 2016;14:87.
21. Giesinger JM, Loth FL, Aaronson NK, Arraras JI, Caocci G, Efficace F, et al. Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol. 2020;118:1–8.

22. Prado CMM, Birdsell LA, Baracos VE. The emerging role of computerized tomography in assessing cancer cachexia. Curr Opin Support Palliat Care. 2009;3(4):269–75.

23. Mitropoulos N, Baumgartner R, Heymsfield S, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol. 1998;85(1):115–22.

24. Wendel-Vos GW, Schuit AJ, Saris WH, Kromhout D. Reproducibility and relative validity of the short questionnaire to assess health-enhancing physical activity. J Clin Epidemiol. 2003;56(12):1163–9.

25. Van Leersum N, Snijders H, Henneman D, Kofschoten N, Gooiker G, Ten Berge M, et al. The Dutch surgical colorectal audit. Eur J Surg Oncol. 2013;39(10):1063–70.

26. Ganz PA. Impact of tamoxifen on adjuvant therapy symptoms, functioning and quality of life. J Natl Cancer Inst Monogr. 2001;(30):130–4.

27. Desquiblet L, Mariotti F. Dose-response analyses using restricted cubic spline functions in public health research. Stat Med. 2010;29(9):1037–57.

28. Tamhane AR, Westfall AO, Burkholder GA, Cutter GR. Prevalence odds ratio versus prevalence ratio: choice comes with consequences. Stat Med. 2016;35(30):5730–5.

29. Dodson S, Baracos VE, Jatoi A, Evans WJ, Cell a D, Dalton JT, et al. Muscle wasting in cancer cachexia: clinical implications, di-agnosis, and emerging treatment strategies. Annu Rev Med. 2011;62:265–79.

30. Williams GR, Deal AM, Muss HB, Weinberg MS, Sanoff HK, Nyrop KA, et al. Skeletal muscle measures and physical function in older adults with cancer: sarcopenia or myopenia? Oncotarget. 2017;8(20):33658–65.

31. Sjöblom B, Grenberg BH, Wentzel-Larsen T, Baracos VE, Hjermstad MJ, Aas N, et al. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer. Clin Nutr. 2016;35(6):1386–93.

32. Fujivara N, Nakagawa H, Kudo Y, Tateishi R, Taguri M, Watadani T, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol. 2015;63(1):131–40.

33. Rier HN, Jager A, Sleijfer S, van Rosmalen J, Kock MC, Levin M-D. Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy. Breast. 2017;31:9–15.

34. van Dijk DP, Bakens MJ, Coulse'n MM, Rensen SS, van Dam RM, Bours MJ, et al. Low skeletal muscle radiation attenuation and visceral adiposity are associated with overall survival and surgical site infections in patients with pancreatic cancer. J Cachexia Sarcopenia Muscle. 2017;8(2):317–26.

35. Blauwhof-Buskermolen S, Versteeg KS, de van der Schueren MA, Den Braver NR, Berkhof J, Langius JA, et al. Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. J Clin Oncol. 2016;34(12):1339–44.

36. Ebadi M, Martin L, Ghosh S, Field CJ, Lehner R, Baracos VE, et al. Subcutaneous adiposity is an independent predictor of mortality in cancer patients. Br J Cancer. 2017;117(1):148–55.

37. Antoun S, Lanoy E, Iacovelli R, Albigers-Sauvin L, Loriot Y, Merad-Taoufik M, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer. 2013;119(18):3377–84.

38. van Baar H, Beijer S, Bours M, Weijenberg M, van Zutphen M, van Raam A, van der Zaag H, et al. Lower muscle density is associated with lower overall and disease-free survival in early-stage colorectal cancer patients. J Cancer Res Clin Oncol. 2018;11:9–.

39. Van Hollebeke RB, Cushman M, Schlueter EF, Allison MA. Abdominal muscle density is inversely related to adiposity inflammatory mediators. Med Sci Sports Exerc. 2018;50(7):1495–501.

40. Margadant C, Bruns E, Sloothaak D, van Duijvendijk P, van Raam A, van der Zaag H, et al. Lower muscle density is associated with major postoperative complications in older patients after surgery for colorectal cancer. Eur J Surg Oncol. 2016;42(11):1654–9.

41. Xiao J, Caan BJ, Weltzie'n E, Cespedes Feliciano EM, Kroenke CH, Meyerhardt JA, et al. Associations of pre-existing co-morbidities with skeletal muscle mass and radiodensity in patients with non-metastatic colorectal cancer. J Cachexia Sarcopenia Muscle. 2018;9(4):654–63.

42. Cooper R, Popham M, Santanasto AJ, Hardy R, Glynn NW, Kuh D. Are BMI and inflammatory markers independently associated with physical fatigability in old age? Int J Obes. 2019;43(4):832–41.

43. Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11(1):11–8.

44. Thomas EL, Bell JD. Influence of undersampling on magnetic resonance imaging measurements of intra-abdominal adipose tissue. Int J Obes. 2003;27(2):211–8.

45. Shuster A, Patlas M, Pinthus JH, Mourtzakis M. The clinical importance of visceral adiposity: a critical review of methods for visceral adipose tissue analysis. Br J Radiol. 2012;85(1009):1–10.

46. Comprehensive Cancer Center the Netherlands (2019) Guideline Colorectal carcinoma. https://www.oncoline.nl/ colorectalcarcinoom. Accessed August 2020.

Publisher's note Springer Nature remains neutral with regard to jurisdic-tional claims in published maps and institutional affiliations.